The University of Pittsburgh Cancer Institute (UPCI) Investigational Drug Service (IDS) is directed by Brian M. Miller, PharmD who is assisted by Elizabeth A. Paul, RPh and a pharmacy technician, Kristine M. Fischl. In addition, the clinic pharmacy that works in tandem with the IDS has three full-time pharmacy technicians, four full-time pharmacists, and two part-time pharmacists. These individuals also participate in treating patients enrolled in protocol treatments mainly through order-entry, mixing chemotherapy, and dispensing provided oral medication. The IDS oversees all pharmacy procedures and processes at the UPCI central and community clinical sites and the Clinical and Translational Research Center (CTRC) where UPCI sponsored studies are implemented and most Phase I studies take place. The IDS coordinate all pharmacy procedures associated with UPCI drug-related research protocols. The goal of the IDS is to ensure that the procurement, receipt, storage, accountability, preparation, dispensing, labeling, and shipping of investigational drugs are performed in accordance with all state and federal laws, Joint Commission on Accreditation of Healthcare Organizations (JCAHO), and the local IRB approved protocol guidelines. Clinical recommendations for drug therapy, monitoring plans for a regimen, managing adverse events, and dose calculations are made with respect to the treatment of patients. Additional responsibilities of the IDS include reviewing all approved IRB protocols, standard chemotherapy and protocol regimens, supportive care regimens (antiemetics and other premedications), and investigational drug policies and procedures. UPCI's Off-site locations require special efforts to ensure rigorous and successful implementation, coordination, and monitoring clinical protocols. Throughout the entire network of cancer sites, the IDS provides oversight and monitoring for all pharmacy related activities. IDS also implements a quality assurance program, which includes labeling drugs per protocol and placing specific labeling on each medication to ensure proper dispensing, and an education program of pharmacists and/or pharmacy technicians for new protocols and treatments, inventory control, and optimized patient care.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-24
Application #
8382692
Study Section
Special Emphasis Panel (ZCA1-RTRB-L)
Project Start
Project End
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
24
Fiscal Year
2012
Total Cost
$114,172
Indirect Cost
$78,573
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Sun, Weijing; Patel, Anuj; Normolle, Daniel et al. (2018) A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma. Cancer :
Krivinko, Josh M; Erickson, Susan L; Ding, Ying et al. (2018) Synaptic Proteome Compensation and Resilience to Psychosis in Alzheimer's Disease. Am J Psychiatry 175:999-1009
Chartoumpekis, Dionysios V; Yagishita, Yoko; Fazzari, Marco et al. (2018) Nrf2 prevents Notch-induced insulin resistance and tumorigenesis in mice. JCI Insight 3:
Christner, Susan; Guo, Jianxia; Parise, Robert A et al. (2018) Liquid chromatography-tandem mass spectrometric assay for the quantitation of the novel radiation protective agent and radiation mitigator JP4-039 in murine plasma. J Pharm Biomed Anal 150:169-175
Laymon, Charles M; Minhas, Davneet S; Becker, Carl R et al. (2018) Image-Based 2D Re-Projection for Attenuation Substitution in PET Neuroimaging. Mol Imaging Biol 20:826-834
Benoist, Guillemette E; van der Meulen, Eric; van Oort, Inge M et al. (2018) Development and Validation of a Bioanalytical Method to Quantitate Enzalutamide and its Active Metabolite N-Desmethylenzalutamide in Human Plasma: Application to Clinical Management of Patients With Metastatic Castration-Resistant Prostate Cancer. Ther Drug Monit 40:222-229
Singh, Krishna B; Hahm, Eun-Ryeong; Rigatti, Lora H et al. (2018) Inhibition of Glycolysis in Prostate Cancer Chemoprevention by Phenethyl Isothiocyanate. Cancer Prev Res (Phila) 11:337-346
Li, Chunlei; Song, Baobao; Santos, Patricia M et al. (2018) Hepatocellular cancer-derived alpha fetoprotein uptake reduces CD1 molecules on monocyte-derived dendritic cells. Cell Immunol :
Thakur, Prakash C; Miller-Ocuin, Jennifer L; Nguyen, Khanh et al. (2018) Inhibition of endoplasmic-reticulum-stress-mediated autophagy enhances the effectiveness of chemotherapeutics on pancreatic cancer. J Transl Med 16:190
Posluszny, Donna M; Bovbjerg, Dana H; Agha, Mounzer E et al. (2018) Patient and family caregiver dyadic adherence to the allogeneic hematopoietic cell transplantation medical regimen. Psychooncology 27:354-358

Showing the most recent 10 out of 1187 publications